Nuvalent (NUVL) Stock Forecast, Price Target & Predictions
NUVL Stock Forecast
Nuvalent stock forecast is as follows: an average price target of $107.83 (represents a 20.44% upside from NUVL’s last price of $89.53) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
NUVL Price Target
The average price target for Nuvalent (NUVL) is $107.83 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $135.00 to $97.00. This represents a potential 20.44% upside from NUVL's last price of $89.53.
NUVL Analyst Ratings
According to 10 Wall Street analysts, Nuvalent's rating consensus is 'Buy'. The analyst rating breakdown for NUVL stock is 0 'Strong Buy' (0.00%), 9 'Buy' (90.00%), 1 'Hold' (10.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Nuvalent Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 24, 2024 | David Dai | UBS | $100.00 | $93.71 | 6.71% | 11.69% |
| Sep 16, 2024 | Kelsey Goodwin | Guggenheim | $105.00 | $110.25 | -4.76% | 17.28% |
| Sep 16, 2024 | Bradley Canino | Stifel Nicolaus | $135.00 | $87.45 | 54.37% | 50.79% |
| Sep 16, 2024 | Christopher Raymond | Raymond James | $100.00 | $87.45 | 14.35% | 11.69% |
| Jul 10, 2024 | Bradley Canino | Stifel Nicolaus | $115.00 | $73.63 | 56.19% | 28.45% |
| Apr 17, 2024 | Roger Song | Jefferies | $97.00 | $64.75 | 49.81% | 8.34% |
| Apr 01, 2024 | Christopher Liu | Leerink Partners | $110.00 | $75.09 | 46.49% | 22.86% |
The latest Nuvalent stock forecast, released on Oct 24, 2024 by David Dai from UBS, set a price target of $100.00, which represents a 6.71% increase from the stock price at the time of the forecast ($93.71), and a 11.69% increase from NUVL last price ($89.53).
Nuvalent Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 4 | 7 |
| Avg Price Target | $100.00 | $110.00 | $108.86 |
| Last Closing Price | $89.53 | $89.53 | $89.53 |
| Upside/Downside | 11.69% | 22.86% | 21.59% |
In the current month, the average price target of Nuvalent stock is $100.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 11.69% increase as opposed to Nuvalent's last price of $89.53. This month's average price target is down -9.09% compared to last quarter, and down -8.14% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 24, 2024 | UBS | - | Neutral | Initialise |
| Sep 16, 2024 | Guggenheim | Buy | Buy | Hold |
| Sep 16, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 16, 2024 | Wedbush | Outperform | Outperform | Hold |
| Sep 16, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 16, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 29, 2024 | Barclays | - | Overweight | Initialise |
| Apr 17, 2024 | Jefferies | - | Buy | Initialise |
| Apr 01, 2024 | Leerink Partners | - | Outperform | Upgrade |
| Aug 08, 2023 | SVB Leerink | - | Outperform | Initialise |
Nuvalent's last stock rating was published by UBS on Oct 24, 2024. The company Initialise its NUVL rating from "null" to "Neutral".
Nuvalent Financial Forecast
Nuvalent Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | $12.50M | $666.67K | - | - | - | - | - |
| High Forecast | $12.50M | $666.67K | - | - | - | - | - |
| Low Forecast | $12.50M | $666.67K | - | - | - | - | - |
| # Analysts | 1 | 1 | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Nuvalent's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NUVL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Nuvalent EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict NUVL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Nuvalent's previous annual EBITDA (undefined) of $NaN.
Nuvalent Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-64.50M | $-72.39M | $-65.70M | $-59.87M | $-62.89M | $-60.35M | $-49.30M |
| High Forecast | $-64.50M | $-72.39M | $-65.70M | $-59.87M | $-62.89M | $-52.09M | $-49.30M |
| Low Forecast | $-64.50M | $-72.39M | $-65.70M | $-59.87M | $-62.89M | $-72.42M | $-49.30M |
| Surprise % | - | - | - | - | - | - | - |
Nuvalent's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NUVL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Nuvalent SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Nuvalent's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NUVL last annual SG&A of $NaN (undefined).
Nuvalent EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-1.00 | $-1.12 | $-1.02 | $-0.93 | $-0.97 | $-0.93 | $-0.76 |
| High Forecast | $-1.00 | $-1.12 | $-1.02 | $-0.93 | $-0.97 | $-0.81 | $-0.76 |
| Low Forecast | $-1.00 | $-1.12 | $-1.02 | $-0.93 | $-0.97 | $-1.12 | $-0.76 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Nuvalent's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NUVL previous annual EPS of $NaN (undefined).
Nuvalent Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.15 | $33.86 | 1474.88% | Buy |
| GPCR | Structure Therapeutics | $39.74 | $92.40 | 132.51% | Buy |
| REPL | Replimune Group | $12.02 | $24.20 | 101.33% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $21.48 | $36.33 | 69.13% | Buy |
| VRDN | Viridian Therapeutics | $22.84 | $37.83 | 65.63% | Buy |
| ASND | Ascendis Pharma | $125.77 | $190.21 | 51.24% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| NUVL | Nuvalent | $89.53 | $107.83 | 20.44% | Buy |
| TVTX | Travere Therapeutics | $18.10 | $21.38 | 18.12% | Buy |
| PCVX | Vaxcyte | $106.49 | $124.14 | 16.57% | Buy |
| UTHR | United Therapeutics | $376.80 | $358.20 | -4.94% | Buy |
| ACLX | Arcellx | $86.44 | $71.57 | -17.20% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
NUVL Forecast FAQ
Is Nuvalent a good buy?
Yes, according to 10 Wall Street analysts, Nuvalent (NUVL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 90.00% of NUVL's total ratings.
What is NUVL's price target?
Nuvalent (NUVL) average price target is $107.83 with a range of $97 to $135, implying a 20.44% from its last price of $89.53. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Nuvalent stock go up soon?
According to Wall Street analysts' prediction for NUVL stock, the company can go up by 20.44% (from the last price of $89.53 to the average price target of $107.83), up by 50.79% based on the highest stock price target, and up by 8.34% based on the lowest stock price target.
Can Nuvalent stock reach $130?
NUVL's highest twelve months analyst stock price target of $135 supports the claim that Nuvalent can reach $130 in the near future.
What is Nuvalent's current price target trend?
1 Wall Street analyst forecast a $100 price target for Nuvalent (NUVL) this month, up 11.69% from its last price of $89.53. Compared to the last 3 and 12 months, the average price target increased by 22.86% and increased by 21.59%, respectively.
What are Nuvalent's analysts' financial forecasts?
Nuvalent's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-173M (high $-164M, low $-185M), average SG&A $0 (high $0, low $0), and average EPS is $-2.671 (high $-2.543, low $-2.858). NUVL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $13.17M (high $13.17M, low $13.17M), average EBITDA is $0 (high $0, low $0), average net income is $-262M (high $-262M, low $-262M), average SG&A $0 (high $0, low $0), and average EPS is $-4.062 (high $-4.062, low $-4.062).